QRISK3

There are 44 papers on QRISK3 in aging research: 1 trial and 35 observational studies in people, 4 reviews. The newest story, Nov 9, 2026: “Advanced heart-kidney-metabolic stages share 90 genetic regions”.

Biomarker

44 papers study it10 more mention it16 findings

12 new papers in 30 daysSee all 54 papers on QRISK3

At a glance

QRISK3 predicts high cardiovascular disease risk in one human study and is associated with lipoprotein and incarceration in human studies.

16 findings in 13 papers from 2021 to 2026, 8 of them since June 2026

“Regression analysis identified PANSS change as a predictor of QRISK3 improvement.”
Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trialEuropean archives of psychiatry and clinical neuroscience2026doi:10.1007/s00406-026-02319-6
  • Human trial1
  • Humans35
  • In silico2

Interventions

2

Metformin

upin humans1

1 study
  1. Metformin improves QRISK3 in patients of schizophrenia with metabolic syndrome on atypical antipsychotics (MD = 0.45 (0.07 to 0.83)).

    “metformin: MD = 0.45 (0.07 to 0.83), p = 0.02”

    Human trialin patients of schizophrenia with metabolic syndrome on atypical antipsychotics1000 mg/dayeight weeks

    Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial

    European archives of psychiatry and clinical neuroscience

More on Metformin

Topiramate

upin humans1

1 study
  1. Topiramate improves QRISK3 in patients of schizophrenia with metabolic syndrome on atypical antipsychotics (MD = 0.61 (0.02 to 1.21)).

    “QRISK3 scores improved significantly in both groups [topiramate: MD = 0.61 (0.02 to 1.21), p = 0.04”

    Human trialin patients of schizophrenia with metabolic syndrome on atypical antipsychotics50 mg/dayeight weeks

    Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial

    European archives of psychiatry and clinical neuroscience

More on Topiramate

Upstream

1

Soluble E-selectin

no changein humans1

1 study
  1. Soluble E-selectin was not clearly linked with QRISK3 in humans (women with PCOS).

    “no significant associations were observed with anthropometric measures, lipid parameters, blood pressure or QRISK3 scores.”

    Humanswomen with PCOSfemalesn = 200

    Soluble E-selectin and QRISK3-based Cardiovascular Risk Assessment in Women with Polycystic Ovary Syndrome: A Prospective Case-control Study from India

    Journal of human reproductive sciences

More on Soluble E-selectin

Associations

12

Cardiovascular disease

upin humans1upin silico1

2 studies
  1. QRISK3 predicts cardiovascular disease in humans (external validation cohort) (C-statistic 0.865 in women and 0.834 in men).

    “QRISK3 discrimination in the whole population was excellent (Harrell's C-statistic 0·865 in women and 0·834 in men)”

    Humansexternal validation cohort

    Effect of competing mortality risks on predictive performance of the QRISK3 cardiovascular risk prediction tool in older people and those with comorbidity: external validation population cohort study

    The lancet. Healthy longevity

  2. QRISK3 predicts cardiovascular disease in silico (c-statistics 0.71 to 0.74).

    “Depending on the model, the c-statistics for incident CVD ranged from 0.71 to 0.74 in the UKB test set (16,137 events).”

    In silico

    Heart risk models predicted co-occurring disease risk

    medRxivPreprint

More on Cardiovascular disease

CVD events and/or atherosclerotic plaque progression

upin humans1HR 1.87

1 study
  1. QRISK3 is associated with CVD events and/or atherosclerotic plaque progression in humans (systemic lupus erythematosus without prior CVD events) (HR 1.87; p = 0.027).

    “QRISK3 was the only tool independently associated with CVD events and/or plaque progression (HR:1.87, p = 0.027).”

    Humanssystemic lupus erythematosus without prior CVD events10 years91% femalesn = 111

    Machine learning improves 10-year prediction of atherosclerotic plaque progression and cardiovascular events in systemic lupus erythematosus

    Rheumatology (Oxford, England)

High risk of cardiovascular disease

upin humans1

1 study
  1. QRISK3 predicts high risk of cardiovascular disease in humans (20% (784/3,842)).

    “A QRISK3 score ≥10% was found in 20% (784/3,842) of individuals in the Primary Cohort”

    Humansn = 3,842

    Rapid community "Healthy Heart" screening to identify people at high risk of cardiovascular events

    PloS one

Incarceration

upin humans1

1 study
  1. Incarceration is associated with QRISK3 in humans across both sexes.

    “Incarceration status was significantly associated with higher waist circumference, body mass index, systolic/diastolic blood pressure and 10-year CVD risk (p < 0.01) across both sexes.”

    Humansacross both sexesplasma

    The health burden of incarceration: cardiovascular risk in a Nigerian prison population

    International journal of prison health

More on Incarceration

Lipoprotein

upin humans1

1 study
  1. Lipoprotein is associated with QRISK3 in humans (1.4%, 1.4%, and 1.8%).

    “Median estimated QRISK3 scores increased incrementally across Lp(a) groups (1.4%, 1.4%, and 1.8%, for low-, intermediate-, and high-Lp(a) groups, respectively; p < 0.001)”

    Humansn = 14,848

    Lipoprotein(a) levels and estimated QRISK3 cardiovascular risk in the Randox Health 2025 cohort: a cross-sectional analysis of 14,848 individuals

    Frontiers in cardiovascular medicine

More on Lipoprotein

Random blood sugar

upin humans1

1 study
  1. Random blood sugar is associated with QRISK3 in hypertensive patients.

    “Correlation analysis revealed significant associations between age, systolic blood pressure, and RBS with CVD risk scores.”

    Humansin hypertensive patients

    Decade of Risk: Predicting Ten-year Cardiovascular Disease Events (Stroke/myocardial Infarction) in Hypertensive Patients at a Tertiary Care Institute in Jharkhand

    Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine

More on Random blood sugar

Systolic blood pressure

upin humans1

1 study
  1. Systolic blood pressure is associated with QRISK3 in hypertensive patients.

    “Correlation analysis revealed significant associations between age, systolic blood pressure, and RBS with CVD risk scores.”

    Humansin hypertensive patients

    Decade of Risk: Predicting Ten-year Cardiovascular Disease Events (Stroke/myocardial Infarction) in Hypertensive Patients at a Tertiary Care Institute in Jharkhand

    Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine

More on Systolic blood pressure

PANSS

downin humans1

1 study
  1. PANSS predicts QRISK3 in schizophrenia with metabolic syndrome.

    “Regression analysis identified PANSS change as a predictor of QRISK3 improvement.”

    Human trialin schizophrenia with metabolic syndrome

    Efficacy and safety of add-on topiramate vs. metformin on cardiometabolic profile in patients of schizophrenia on atypical antipsychotics with metabolic syndrome: an active-controlled, rater-blinded, parallel-design randomized controlled trial

    European archives of psychiatry and clinical neuroscience

10-year cardiovascular risk

mixedin humans1

1 study
  1. QRISK3 predicts 10-year cardiovascular risk in humans (Median 2.5% (IQR 1.1-4.8%); 148 (95%) below the 10% treatment threshold).

    “The median 10-year predicted CV risk in this group was only 2.5% (IQR = 1.1-4.8%), with 148 (95%) falling below the 10% threshold for active risk management.”

    HumansIndividuals with incident vascular events who would have been eligible for an earlier health checkn = 155

    Potential of earlier primary care health checks for prevention of cardiovascular events in younger age groups: population-based study in the United Kingdom

    BMC medicine

More on 10-year cardiovascular risk

Deep white matter hyperintensities

upin humans1OR 1.067

1 study
  1. QRISK3 predicts deep white matter hyperintensities in humans (unadjusted logistic regression) (OR 1.067, p = .027).

    “QRisk (OR=1.067, p = .027) was slightly better at predicting DWM score of 2 or more, than ASCVD (OR=1.053, p = .023).”

    Humansunadjusted logistic regressionbrainn = 41

    Educational Levels and Cardiovascular Risk Scores to predict Deep White Matter Hyperintensities in Fazekas Scale

    AAIC 2025 abstract

All 12

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 0Jan 2026: 5Feb 2026: 4Mar 2026: 3Apr 2026: 2May 2026: 0Jun 2026: 5Jul 2026: 2Aug 2026: 4Sep 2026: 5Oct 2026: 9Nov 2026: 241 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Advanced heart-kidney-metabolic stages share 90 genetic regions

In 391,836 UK Biobank participants, a 90-region genetic core spanned stages 2–4 of the syndrome, while stage 1 differed substantially.In 391,836 UK Biobank participants, a 90-region genetic core spanned stages 2–4 of the syndrome, while stage 1 differed substantially.

Genetic association · 391,836 peopleCardiovascular-kidney-metabolic syndrome

See all 54 papers on QRISK3